{
  "section": "objectives_endpoints",
  "rating": "POOR",
  "status": "fail",
  "extraction_validation": {
    "sections_read": [
      "2.1",
      "2.2",
      "8",
      "8.1",
      "8.2.1",
      "8.2.2",
      "8.2.2.1",
      "8.2.2.2",
      "8.2.2.3",
      "8.2.2.4",
      "9.2",
      "10.1",
      "10.1.5",
      "10.9",
      "11"
    ],
    "elements_per_section": {
      "2.1": 1,
      "2.2": 4,
      "8": 3,
      "8.1": 2,
      "8.2.1": 1,
      "8.2.2": 3,
      "8.2.2.1": 7,
      "8.2.2.2": 8,
      "8.2.2.3": 8,
      "8.2.2.4": 4,
      "9.2": 3,
      "10.1": 1,
      "10.1.5": 11,
      "10.9": 3,
      "11": 4
    },
    "elements_extracted": 63,
    "elements_in_evaluation_table": 63,
    "elements_in_missing_from_generated_sap": 28,
    "counts_match": true
  },
  "evaluation_table": [
    {
      "component": "Primary Objective",
      "evaluation_type": "exact_match",
      "original_sap_text": "The primary objective of the study is: To demonstrate CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) during the Induction Study Period",
      "generated_sap_text": "To demonstrate CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) up to Cycle 6 during the Induction Study Period",
      "protocol_text": "To demonstrate CT-P16 is similar to EU-Approved Avastin in terms of efficacy as determined by objective response rate (ORR) up to Cycle 6 during the Induction Study Period",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "Secondary Objective - Efficacy",
      "evaluation_type": "exact_match",
      "original_sap_text": "To evaluate additional efficacy profiles including ORR during the Whole Study Period, response duration, time to progression (TTP), progression-free survival (PFS), and overall survival (OS)",
      "generated_sap_text": "To evaluate additional efficacy profiles including ORR during the Whole Study Period, response duration, time to progression (TTP), progression-free survival (PFS), and overall survival (OS)",
      "protocol_text": "To evaluate additional efficacy profiles including ORR during the Whole Study Period, response duration, time to progression (TTP), progression-free survival (PFS), and overall survival (OS)",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "Secondary Objective - PK",
      "evaluation_type": "exact_match",
      "original_sap_text": "To evaluate the Pharmacokinetic (PK) parameter of trough serum concentration (Ctrough)",
      "generated_sap_text": "To evaluate the pharmacokinetics (PK) of trough serum concentration (Ctrough)",
      "protocol_text": "To evaluate the pharmacokinetics (PK) of trough serum concentration (Ctrough)",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "Secondary Objective - Safety",
      "evaluation_type": "exact_match",
      "original_sap_text": "To evaluate safety profile including immunogenicity",
      "generated_sap_text": "To evaluate safety profile including immunogenicity",
      "protocol_text": "To evaluate safety profile including immunogenicity",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "Secondary Objective - QoL",
      "evaluation_type": "exact_match",
      "original_sap_text": "To evaluate quality of life (QoL)",
      "generated_sap_text": "To evaluate quality of life (QoL)",
      "protocol_text": "To evaluate quality of life (QoL)",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "Efficacy Endpoint Determination",
      "evaluation_type": "semantic",
      "original_sap_text": "The primary endpoint, ORR during the Induction Study Period, and the secondary endpoint, ORR during the Whole Study Period, will be determined by the BOR.",
      "generated_sap_text": "The primary efficacy endpoint is the Objective Response Rate (ORR), defined as the proportion of patients achieving a Best Overall Response (BOR)",
      "protocol_text": "The primary endpoint, ORR during the Induction Study Period, and the secondary endpoint, ORR during the Whole Study Period, will be determined by the best overall response (BOR).",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches concept."
    },
    {
      "component": "Confirmation of Response",
      "evaluation_type": "semantic",
      "original_sap_text": "For CR or PR, BOR must be confirmed by the subsequent assessment.",
      "generated_sap_text": "While the primary endpoint requires confirmation (as per RECIST 1.1)",
      "protocol_text": "For CR or PR, BOR must be confirmed by the subsequent assessment based on the RECIST v.1.1",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches concept."
    },
    {
      "component": "BOR Categories",
      "evaluation_type": "semantic",
      "original_sap_text": "Categorization of BOR will use the following response categories: CR, PR, SD, PD and NE.",
      "generated_sap_text": "Descriptive statistics for the primary endpoint will include the number and percentage of responders (CR + PR) and non-responders (SD, PD, NE) per treatment group.",
      "protocol_text": "Categorization of overall response at each visit will be based on RECIST v.1.1 using the following response categories: CR, PR, SD, PD, and inevaluable (NE)",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches categories."
    },
    {
      "component": "Primary Endpoint Definition",
      "evaluation_type": "exact_match",
      "original_sap_text": "The primary efficacy endpoint is ORR based on BOR during the Induction Study Period by RECIST version 1.1",
      "generated_sap_text": "The primary efficacy endpoint is the Objective Response Rate (ORR), defined as the proportion of patients achieving a Best Overall Response (BOR) of either Complete Response (CR) or Partial Response (PR) during the Induction Study Period (up to Cycle 6) as determined by an Independent Tumor Review Committee (central review) using RECIST v.1.1.",
      "protocol_text": "The primary efficacy endpoint will be the ORR based on BOR during the Induction Study Period by RECIST v.1.1",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "ORR Definition",
      "evaluation_type": "semantic",
      "original_sap_text": "The ORR is defined as the proportion of patients with a confirmed BOR of CR or PR (the 'responder').",
      "generated_sap_text": "defined as the proportion of patients achieving a Best Overall Response (BOR) of either Complete Response (CR) or Partial Response (PR)",
      "protocol_text": "Objective response rate will be calculated as the number of patients with a response of CR or PR divided by the number of patients in the corresponding population.",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "Secondary Endpoint - ORR Whole Study",
      "evaluation_type": "exact_match",
      "original_sap_text": "For the secondary efficacy endpoint, ORR based on BOR during the Whole Study Period by RECIST version 1.1 will be analyzed.",
      "generated_sap_text": "ORR based on BOR during the Whole Study Period by RECIST v.1.1",
      "protocol_text": "ORR based on BOR during the Whole Study Period by RECIST v.1.1",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "Time-to-Event Analysis List",
      "evaluation_type": "exact_match",
      "original_sap_text": "A time-to-event analysis will be undertaken for each of the response duration, TTP, PFS, and OS in the ITT and PP population.",
      "generated_sap_text": "Time-to-event (TTE) endpoints will be analyzed using the ITT and PP populations. Progression-Free Survival (PFS)... Time to Progression (TTP)... Overall Survival (OS)... Response Duration...",
      "protocol_text": "A time-to-event analysis will be undertaken for each of the response duration, TTP, PFS, and OS in the ITT and PP population",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "TTE Reporting Units",
      "evaluation_type": "semantic",
      "original_sap_text": "All time-to-event data will be reported in months with reasons for an event/censoring and summarized by treatment group.",
      "generated_sap_text": "Median TTE and survival rates at specific landmarks (e.g., 6 months, 12 months) will be calculated",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Implies months."
    },
    {
      "component": "Days to Months Conversion",
      "evaluation_type": "exact_match",
      "original_sap_text": "Time-to-event in days will be converted to months by dividing the number of days by 30.4 (365.25 days/12 months).",
      "generated_sap_text": "null",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Time-to-event in days will be converted to months by dividing the number of days by 30.4 (365.25 days/12 months).",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Conversion factor missing."
    },
    {
      "component": "Response Duration Definition",
      "evaluation_type": "semantic",
      "original_sap_text": "Response duration is defined as the time between initial response (CR or PR) that is confirmed by the subsequent assessment after study treatment administration and PD/recurrence or death from any cause (whichever occurs first).",
      "generated_sap_text": "Response Duration: Time from the first documented response (CR or PR) until the first documentation of PD or death (among responders only).",
      "protocol_text": "Response duration: the time between initial response (CR or PR) and PD/recurrence",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "Response Duration Event",
      "evaluation_type": "semantic",
      "original_sap_text": "PD/recurrence or death that occurred on or before beginning another new anticancer therapy will be regarded as an event.",
      "generated_sap_text": "Patients starting a new anti-cancer therapy prior to PD will be censored",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Implied by censoring rule."
    },
    {
      "component": "Response Duration Censoring (No event)",
      "evaluation_type": "semantic",
      "original_sap_text": "Censoring will be defined as following: No event and no anticancer therapy - Last tumor assessment date",
      "generated_sap_text": "Patients alive and without PD at the time of data cutoff/study completion will be censored at the date of the last adequate tumor assessment.",
      "protocol_text": "if a patient has no event, it will be calculated censoring at the date of last adequate radiological assessment",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "Response Duration Censoring (New therapy)",
      "evaluation_type": "semantic",
      "original_sap_text": "Censoring will be defined as following: Initiation of New anticancer therapy - Last tumor assessment date before anticancer therapy",
      "generated_sap_text": "Patients starting a new anti-cancer therapy prior to PD will be censored at the date of the last adequate tumor assessment prior to the start of the new therapy.",
      "protocol_text": "If a patient receives another new anticancer therapy, it will be censored at the date of adequate radiological assessment, without disease progression/or recurrence, before starting another anticancer therapy.",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "Response Duration Censoring (Missing assessments)",
      "evaluation_type": "semantic",
      "original_sap_text": "Censoring will be defined as following: Event after missing two or more tumor assessment* - Last tumor assessment date before event",
      "generated_sap_text": "If PD or death occurs after missing two or more consecutive scheduled tumor assessments, the patient will be censored at the date of the last adequate tumor assessment prior to the missing visits.",
      "protocol_text": "If disease progression or death is documented after missing two or more tumor assessments, the patient will be censored for PFS at the date of their last adequate tumor assessment",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "Response Duration Missing Exception",
      "evaluation_type": "semantic",
      "original_sap_text": "* If there is only one missing tumor assessment before an event, then it will be considered as an event case. Otherwise, it will be considered as a censoring case.",
      "generated_sap_text": "If PD or death occurs after missing two or more consecutive scheduled tumor assessments, the patient will be censored",
      "protocol_text": "If disease progression or death is documented after missing one tumor assessment, the PFS time of these patients will be calculated assuming the event occurred on the date of progression (or death).",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Implied."
    },
    {
      "component": "Response Duration Formula",
      "evaluation_type": "exact_match",
      "original_sap_text": "Response duration (months) = ([Date of Event/Censoring \u2013 Date of First known CR/PR that is confirmed by the subsequent assessment] +1)/30.4",
      "generated_sap_text": "null",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Response duration (months) = ([Date of Event/Censoring \u2013 Date of First known CR/PR that is confirmed by the subsequent assessment] +1)/30.4",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Formula missing."
    },
    {
      "component": "TTP Definition",
      "evaluation_type": "exact_match",
      "original_sap_text": "TTP is defined as time from randomization to determined PD/recurrence.",
      "generated_sap_text": "Time to Progression (TTP): Time from randomization until the first documentation of PD.",
      "protocol_text": "TTP: the time from randomization until PD/recurrence",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "TTP Event",
      "evaluation_type": "semantic",
      "original_sap_text": "PD/recurrence that occurred on or before beginning another new anticancer therapy will be regarded as an event.",
      "generated_sap_text": "Patients starting a new anti-cancer therapy prior to PD will be censored",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Implied."
    },
    {
      "component": "TTP Censoring (No assessment)",
      "evaluation_type": "exact_match",
      "original_sap_text": "Censoring will be defined as following: No tumor assessment - The date of randomization",
      "generated_sap_text": "null",
      "protocol_text": "Any patient without any tumor assessment during the study will be censored at the date of randomization.",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Censoring will be defined as following: No tumor assessment - The date of randomization",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Specific censoring rule missing."
    },
    {
      "component": "TTP Censoring (No event)",
      "evaluation_type": "semantic",
      "original_sap_text": "Censoring will be defined as following: No event and no anticancer therapy - Last tumor assessment date",
      "generated_sap_text": "Patients alive and without PD at the time of data cutoff/study completion will be censored at the date of the last adequate tumor assessment.",
      "protocol_text": "if a patient has no event, it will be calculated censoring at the date of last adequate radiological assessment",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "TTP Censoring (New therapy)",
      "evaluation_type": "semantic",
      "original_sap_text": "Censoring will be defined as following: Initiation of New anticancer therapy - Last tumor assessment date before anticancer therapy",
      "generated_sap_text": "Patients starting a new anti-cancer therapy prior to PD will be censored at the date of the last adequate tumor assessment prior to the start of the new therapy.",
      "protocol_text": "If a patient receives another new anticancer therapy, it will be censored at the date of adequate radiological assessment, without disease progression/or recurrence, before starting another anticancer therapy.",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "TTP Censoring (Missing assessments)",
      "evaluation_type": "semantic",
      "original_sap_text": "Censoring will be defined as following: Event after missing two or more tumor assessment* - Last tumor assessment date before event",
      "generated_sap_text": "If PD or death occurs after missing two or more consecutive scheduled tumor assessments, the patient will be censored at the date of the last adequate tumor assessment prior to the missing visits.",
      "protocol_text": "If disease progression or death is documented after missing two or more tumor assessments, the patient will be censored for PFS at the date of their last adequate tumor assessment",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "TTP Missing Exception",
      "evaluation_type": "semantic",
      "original_sap_text": "* If there is only one missing tumor assessment before an event, then it will be considered as an event case. Otherwise, it will be considered as a censoring case.",
      "generated_sap_text": "If PD or death occurs after missing two or more consecutive scheduled tumor assessments, the patient will be censored",
      "protocol_text": "If disease progression or death is documented after missing one tumor assessment, the PFS time of these patients will be calculated assuming the event occurred on the date of progression (or death).",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Implied."
    },
    {
      "component": "TTP Formula",
      "evaluation_type": "exact_match",
      "original_sap_text": "TTP (months) = ([Date of Event/Censoring \u2013 Date of Randomization] +1)/30.4",
      "generated_sap_text": "null",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "TTP (months) = ([Date of Event/Censoring \u2013 Date of Randomization] +1)/30.4",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Formula missing."
    },
    {
      "component": "PFS Definition",
      "evaluation_type": "exact_match",
      "original_sap_text": "PFS is defined as time from randomization to determined PD/recurrence or death from any cause (whichever occurs first).",
      "generated_sap_text": "Progression-Free Survival (PFS): Time from randomization until the first documentation of PD (per RECIST v.1.1) or death due to any cause.",
      "protocol_text": "PFS: the time from randomization until PD/recurrence or death due to any cause, whichever occurs first",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "PFS Event",
      "evaluation_type": "semantic",
      "original_sap_text": "PD/recurrence or death that occurred on or before beginning another new anticancer therapy will be regarded as an event.",
      "generated_sap_text": "Patients starting a new anti-cancer therapy prior to PD will be censored",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Implied."
    },
    {
      "component": "PFS Censoring (No assessment)",
      "evaluation_type": "exact_match",
      "original_sap_text": "Censoring will be defined as following: No tumor assessment - The date of randomization",
      "generated_sap_text": "null",
      "protocol_text": "Any patient without any tumor assessment during the study will be censored at the date of randomization.",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Censoring will be defined as following: No tumor assessment - The date of randomization",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Specific censoring rule missing."
    },
    {
      "component": "PFS Censoring (No event)",
      "evaluation_type": "semantic",
      "original_sap_text": "Censoring will be defined as following: No event and no anticancer therapy - Last tumor assessment date",
      "generated_sap_text": "Patients alive and without PD at the time of data cutoff/study completion will be censored at the date of the last adequate tumor assessment.",
      "protocol_text": "if a patient has no event, it will be calculated censoring at the date of last adequate radiological assessment",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "PFS Censoring (New therapy)",
      "evaluation_type": "semantic",
      "original_sap_text": "Censoring will be defined as following: Initiation of New anticancer therapy - Last tumor assessment date before anticancer therapy",
      "generated_sap_text": "Patients starting a new anti-cancer therapy prior to PD will be censored at the date of the last adequate tumor assessment prior to the start of the new therapy.",
      "protocol_text": "If a patient receives another new anticancer therapy, it will be censored at the date of adequate radiological assessment, without disease progression/or recurrence, before starting another anticancer therapy.",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "PFS Censoring (Missing assessments)",
      "evaluation_type": "semantic",
      "original_sap_text": "Censoring will be defined as following: Event after missing two or more tumor assessment* - Last tumor assessment date before event",
      "generated_sap_text": "If PD or death occurs after missing two or more consecutive scheduled tumor assessments, the patient will be censored at the date of the last adequate tumor assessment prior to the missing visits.",
      "protocol_text": "If disease progression or death is documented after missing two or more tumor assessments, the patient will be censored for PFS at the date of their last adequate tumor assessment",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "PFS Missing Exception",
      "evaluation_type": "semantic",
      "original_sap_text": "* If there is only one missing tumor assessment before an event, then it will be considered as an event case. Otherwise, it will be considered as a censoring case.",
      "generated_sap_text": "If PD or death occurs after missing two or more consecutive scheduled tumor assessments, the patient will be censored",
      "protocol_text": "If disease progression or death is documented after missing one tumor assessment, the PFS time of these patients will be calculated assuming the event occurred on the date of progression (or death).",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Implied."
    },
    {
      "component": "PFS Formula",
      "evaluation_type": "exact_match",
      "original_sap_text": "PFS (months) = ([Date of Event/Censoring \u2013 Date of Randomization] +1)/30.4",
      "generated_sap_text": "null",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "PFS (months) = ([Date of Event/Censoring \u2013 Date of Randomization] +1)/30.4",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Formula missing."
    },
    {
      "component": "OS Definition",
      "evaluation_type": "exact_match",
      "original_sap_text": "OS is defined as time from randomization to death from any cause.",
      "generated_sap_text": "Overall Survival (OS): Time from randomization until death due to any cause.",
      "protocol_text": "OS: the time from randomization until death due to any cause",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "OS Event",
      "evaluation_type": "semantic",
      "original_sap_text": "Death will be regarded as an event.",
      "generated_sap_text": "Time from randomization until death due to any cause.",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Implied."
    },
    {
      "component": "OS Censoring",
      "evaluation_type": "exact_match",
      "original_sap_text": "Censoring will be defined as following: Non-death - Last known alive date",
      "generated_sap_text": "null",
      "protocol_text": "for patients whose status is unknown, data will be censored at the time when the patient is last known to be alive.",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Censoring will be defined as following: Non-death - Last known alive date",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Specific censoring rule missing."
    },
    {
      "component": "OS Formula",
      "evaluation_type": "exact_match",
      "original_sap_text": "OS (months) = ([Date of Event/Censoring \u2013 Date of Randomization] +1)/30.4",
      "generated_sap_text": "null",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "OS (months) = ([Date of Event/Censoring \u2013 Date of Randomization] +1)/30.4",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Formula missing."
    },
    {
      "component": "PK Parameter Definition",
      "evaluation_type": "semantic",
      "original_sap_text": "PK parameter is the observed Ctrough following drug administration; calculated from the pre-dose concentration of the next dose.",
      "generated_sap_text": "Ctrough: Trough serum concentration",
      "protocol_text": "The Ctrough (prior to next dose) at each cycle during the Induction Study Period, and Ctrough during the Maintenance Study Period will be analyzed.",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "less_detailed",
      "omitted_content": "calculated from the pre-dose concentration of the next dose",
      "omission_impact": "low",
      "result": "acceptable",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Definition is less detailed but consistent."
    },
    {
      "component": "PK Exclusion i",
      "evaluation_type": "exact_match",
      "original_sap_text": "The samples in following cases are excluded from calculation of Ctrough; i) Post-dose concentration in the Induction Study Period",
      "generated_sap_text": "null",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "The samples in following cases are excluded from calculation of Ctrough; i) Post-dose concentration in the Induction Study Period",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Exclusion criteria missing."
    },
    {
      "component": "PK Exclusion ii",
      "evaluation_type": "exact_match",
      "original_sap_text": "The samples in following cases are excluded from calculation of Ctrough; ii) interval between the last dose date and sampling date at EOT < 18 days",
      "generated_sap_text": "null",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "The samples in following cases are excluded from calculation of Ctrough; ii) interval between the last dose date and sampling date at EOT < 18 days",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Exclusion criteria missing."
    },
    {
      "component": "TEAE Definition",
      "evaluation_type": "semantic",
      "original_sap_text": "A Treatment-Emergent Adverse Event (TEAE) is defined as any event not present before exposure to study drug or any event already present that worsen in either severity or frequency after exposure to study drug.",
      "generated_sap_text": "A treatment-emergent abnormality is defined as a post-baseline value that represents a worsening from baseline (either an increase in CTCAE grade or a shift from Normal/Low to High, or Normal/High to Low).",
      "protocol_text": "A treatment-emergent AE is defined as any event not present before exposure to study drug or any event already present that worsens in either severity or frequency after exposure to study drug.",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "contradiction",
      "omitted_content": "none",
      "omission_impact": "potential",
      "result": "problem",
      "issue_type": "contradiction_original",
      "severity": "minor",
      "reasoning": "Generated SAP defines TEAE only in context of labs, missing the general clinical definition."
    },
    {
      "component": "AESI 1",
      "evaluation_type": "exact_match",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Hypersensitivity/IRR",
      "generated_sap_text": "null",
      "protocol_text": "adverse events of special interest (AESIs) (hypersensitivity/infusion-related reactions...",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Hypersensitivity/IRR",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "List of AESIs missing."
    },
    {
      "component": "AESI 2",
      "evaluation_type": "exact_match",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Gastrointestinal perforations and fistulae",
      "generated_sap_text": "null",
      "protocol_text": "gastrointestinal perforations and fistulae",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Gastrointestinal perforations and fistulae",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "List of AESIs missing."
    },
    {
      "component": "AESI 3",
      "evaluation_type": "exact_match",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Wound healing complications",
      "generated_sap_text": "null",
      "protocol_text": "wound healing complications",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Wound healing complications",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "List of AESIs missing."
    },
    {
      "component": "AESI 4",
      "evaluation_type": "exact_match",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Hypertension",
      "generated_sap_text": "null",
      "protocol_text": "hypertension",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Hypertension",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "List of AESIs missing."
    },
    {
      "component": "AESI 5",
      "evaluation_type": "exact_match",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: posterior reversible encephalopathy syndrome (PRES)",
      "generated_sap_text": "null",
      "protocol_text": "posterior reversible encephalopathy syndrome (PRES)",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "posterior reversible encephalopathy syndrome (PRES)",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "List of AESIs missing."
    },
    {
      "component": "AESI 6",
      "evaluation_type": "exact_match",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Proteinuria",
      "generated_sap_text": "null",
      "protocol_text": "proteinuria",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Proteinuria",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "List of AESIs missing."
    },
    {
      "component": "AESI 7",
      "evaluation_type": "exact_match",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: arterial thromboembolism (ATE)",
      "generated_sap_text": "null",
      "protocol_text": "arterial thromboembolism (ATE)",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "arterial thromboembolism (ATE)",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "List of AESIs missing."
    },
    {
      "component": "AESI 8",
      "evaluation_type": "exact_match",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: venous thromboembolism (VTE)",
      "generated_sap_text": "null",
      "protocol_text": "venous thromboembolism (VTE)",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "venous thromboembolism (VTE)",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "List of AESIs missing."
    },
    {
      "component": "AESI 9",
      "evaluation_type": "exact_match",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Hemorrhages",
      "generated_sap_text": "null",
      "protocol_text": "hemorrhages",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Hemorrhages",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "List of AESIs missing."
    },
    {
      "component": "AESI 10",
      "evaluation_type": "exact_match",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: congestive heart failure (CHF)",
      "generated_sap_text": "null",
      "protocol_text": "congestive heart failure (CHF)",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "congestive heart failure (CHF)",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "List of AESIs missing."
    },
    {
      "component": "AESI 11",
      "evaluation_type": "exact_match",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Ovarian failure/fertility.",
      "generated_sap_text": "null",
      "protocol_text": "ovarian failure/fertility",
      "protocol_consulted": "yes",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Ovarian failure/fertility",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "List of AESIs missing."
    },
    {
      "component": "Immunogenicity Assays",
      "evaluation_type": "semantic",
      "original_sap_text": "Immunogenicity assessment consists of both anti-drug antibody (ADA) and neutralizing antibody (NAb) assays.",
      "generated_sap_text": "Immunogenicity, as assessed by the incidence of antidrug antibody and neutralized antidrug antibody.",
      "protocol_text": "Immunogenicity, as assessed by the incidence of antidrug antibody and neutralized antidrug antibody.",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "ADA Transformation",
      "evaluation_type": "exact_match",
      "original_sap_text": "The ADA value tagged assay will be transformed using a log transformation. Transformed ADA value can be obtained using [log3(X/42)] + 1 transformation.",
      "generated_sap_text": "null",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "The ADA value tagged assay will be transformed using a log transformation. Transformed ADA value can be obtained using [log3(X/42)] + 1 transformation.",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Transformation formula missing."
    },
    {
      "component": "NAb Transformation",
      "evaluation_type": "exact_match",
      "original_sap_text": "Transformed NAb value can be obtained using [log2(X/5)] + 1 transformation.",
      "generated_sap_text": "null",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Transformed NAb value can be obtained using [log2(X/5)] + 1 transformation.",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Transformation formula missing."
    },
    {
      "component": "QoL Instruments",
      "evaluation_type": "exact_match",
      "original_sap_text": "QoL will be assessed... using EORTC QLQ. The QLQ core 30 (QLQ-C30) and QLQ lung cancer-specific module (QLQ-LC13) will be used.",
      "generated_sap_text": "QLQ-C30 and QLQ-LC13, using EORTC QLQ",
      "protocol_text": "Quality of Life will be assessed using the validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ). The QLQ core 30 (QLQ-C30) and QLQ lung cancer-specific module (QLQ-LC13) will be used.",
      "protocol_consulted": "yes",
      "matches_original_sap": "yes",
      "detail_level": "match",
      "omitted_content": "none",
      "omission_impact": "none",
      "result": "correct",
      "issue_type": "none",
      "severity": "none",
      "reasoning": "Matches."
    },
    {
      "component": "QoL Raw Score Formula",
      "evaluation_type": "exact_match",
      "original_sap_text": "For all scales, the Raw Score (RS), is the mean of the component items: RS = (I1 + I2 + \u2026 + In)/n",
      "generated_sap_text": "null",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "For all scales, the Raw Score (RS), is the mean of the component items: RS = (I1 + I2 + \u2026 + In)/n",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Formula missing."
    },
    {
      "component": "QoL Functional Score Formula",
      "evaluation_type": "exact_match",
      "original_sap_text": "Then for Functional scales: Score = {1 - (RS-1)/range} \u00d7 100",
      "generated_sap_text": "null",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "Then for Functional scales: Score = {1 - (RS-1)/range} \u00d7 100",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Formula missing."
    },
    {
      "component": "QoL Symptom Score Formula",
      "evaluation_type": "exact_match",
      "original_sap_text": "And for Symptom scales/items and Global health status/QoL: Score = {(RS-1)/range} \u00d7 100",
      "generated_sap_text": "null",
      "protocol_text": "null",
      "protocol_consulted": "no",
      "matches_original_sap": "no",
      "detail_level": "less_detailed",
      "omitted_content": "And for Symptom scales/items and Global health status/QoL: Score = {(RS-1)/range} \u00d7 100",
      "omission_impact": "low",
      "result": "problem",
      "issue_type": "none",
      "severity": "minor",
      "reasoning": "Formula missing."
    }
  ],
  "missing_from_generated_sap": [
    {
      "component": "Days to Months Conversion",
      "original_sap_text": "Time-to-event in days will be converted to months by dividing the number of days by 30.4 (365.25 days/12 months).",
      "protocol_text": null,
      "in_protocol": "no",
      "classification": "acceptable_difference",
      "description": "Specific conversion factor for days to months is missing.",
      "reasoning": "Not in protocol, but standard SAP detail."
    },
    {
      "component": "Response Duration Formula",
      "original_sap_text": "Response duration (months) = ([Date of Event/Censoring \u2013 Date of First known CR/PR that is confirmed by the subsequent assessment] +1)/30.4",
      "protocol_text": null,
      "in_protocol": "no",
      "classification": "acceptable_difference",
      "description": "Specific formula for response duration is missing.",
      "reasoning": "Not in protocol, but standard SAP detail."
    },
    {
      "component": "TTP Censoring (No tumor assessment)",
      "original_sap_text": "Censoring will be defined as following: No tumor assessment - The date of randomization",
      "protocol_text": "Any patient without any tumor assessment during the study will be censored at the date of randomization.",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Censoring rule for patients with no tumor assessment is missing for TTP.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "TTP Formula",
      "original_sap_text": "TTP (months) = ([Date of Event/Censoring \u2013 Date of Randomization] +1)/30.4",
      "protocol_text": null,
      "in_protocol": "no",
      "classification": "acceptable_difference",
      "description": "Specific formula for TTP is missing.",
      "reasoning": "Not in protocol, but standard SAP detail."
    },
    {
      "component": "PFS Censoring (No tumor assessment)",
      "original_sap_text": "Censoring will be defined as following: No tumor assessment - The date of randomization",
      "protocol_text": "Any patient without any tumor assessment during the study will be censored at the date of randomization.",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Censoring rule for patients with no tumor assessment is missing for PFS.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "PFS Formula",
      "original_sap_text": "PFS (months) = ([Date of Event/Censoring \u2013 Date of Randomization] +1)/30.4",
      "protocol_text": null,
      "in_protocol": "no",
      "classification": "acceptable_difference",
      "description": "Specific formula for PFS is missing.",
      "reasoning": "Not in protocol, but standard SAP detail."
    },
    {
      "component": "OS Censoring",
      "original_sap_text": "Censoring will be defined as following: Non-death - Last known alive date",
      "protocol_text": "for patients whose status is unknown, data will be censored at the time when the patient is last known to be alive.",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Censoring rule for OS is missing.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "OS Formula",
      "original_sap_text": "OS (months) = ([Date of Event/Censoring \u2013 Date of Randomization] +1)/30.4",
      "protocol_text": null,
      "in_protocol": "no",
      "classification": "acceptable_difference",
      "description": "Specific formula for OS is missing.",
      "reasoning": "Not in protocol, but standard SAP detail."
    },
    {
      "component": "PK Exclusion i",
      "original_sap_text": "The samples in following cases are excluded from calculation of Ctrough; i) Post-dose concentration in the Induction Study Period",
      "protocol_text": null,
      "in_protocol": "no",
      "classification": "acceptable_difference",
      "description": "Specific PK exclusion criteria missing.",
      "reasoning": "Not in protocol."
    },
    {
      "component": "PK Exclusion ii",
      "original_sap_text": "The samples in following cases are excluded from calculation of Ctrough; ii) interval between the last dose date and sampling date at EOT < 18 days",
      "protocol_text": null,
      "in_protocol": "no",
      "classification": "acceptable_difference",
      "description": "Specific PK exclusion criteria missing.",
      "reasoning": "Not in protocol."
    },
    {
      "component": "AESI 1",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Hypersensitivity/IRR",
      "protocol_text": "hypersensitivity/infusion-related reactions",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Specific AESI missing from list.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "AESI 2",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Gastrointestinal perforations and fistulae",
      "protocol_text": "gastrointestinal perforations and fistulae",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Specific AESI missing from list.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "AESI 3",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Wound healing complications",
      "protocol_text": "wound healing complications",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Specific AESI missing from list.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "AESI 4",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Hypertension",
      "protocol_text": "hypertension",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Specific AESI missing from list.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "AESI 5",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: posterior reversible encephalopathy syndrome (PRES)",
      "protocol_text": "posterior reversible encephalopathy syndrome (PRES)",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Specific AESI missing from list.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "AESI 6",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Proteinuria",
      "protocol_text": "proteinuria",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Specific AESI missing from list.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "AESI 7",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: arterial thromboembolism (ATE)",
      "protocol_text": "arterial thromboembolism (ATE)",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Specific AESI missing from list.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "AESI 8",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: venous thromboembolism (VTE)",
      "protocol_text": "venous thromboembolism (VTE)",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Specific AESI missing from list.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "AESI 9",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Hemorrhages",
      "protocol_text": "hemorrhages",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Specific AESI missing from list.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "AESI 10",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: congestive heart failure (CHF)",
      "protocol_text": "congestive heart failure (CHF)",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Specific AESI missing from list.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "AESI 11",
      "original_sap_text": "The following TEAEs will be considered as TEAEs of special interest: Ovarian failure/fertility.",
      "protocol_text": "ovarian failure/fertility",
      "in_protocol": "yes",
      "classification": "missing_required",
      "description": "Specific AESI missing from list.",
      "reasoning": "Required by protocol."
    },
    {
      "component": "ADA Transformation",
      "original_sap_text": "The ADA value tagged assay will be transformed using a log transformation. Transformed ADA value can be obtained using [log3(X/42)] + 1 transformation.",
      "protocol_text": null,
      "in_protocol": "no",
      "classification": "acceptable_difference",
      "description": "Specific transformation formula missing.",
      "reasoning": "Not in protocol."
    },
    {
      "component": "NAb Transformation",
      "original_sap_text": "Transformed NAb value can be obtained using [log2(X/5)] + 1 transformation.",
      "protocol_text": null,
      "in_protocol": "no",
      "classification": "acceptable_difference",
      "description": "Specific transformation formula missing.",
      "reasoning": "Not in protocol."
    },
    {
      "component": "QoL Raw Score Formula",
      "original_sap_text": "For all scales, the Raw Score (RS), is the mean of the component items: RS = (I1 + I2 + \u2026 + In)/n",
      "protocol_text": null,
      "in_protocol": "no",
      "classification": "acceptable_difference",
      "description": "Specific scoring formula missing.",
      "reasoning": "Not in protocol."
    },
    {
      "component": "QoL Functional Score Formula",
      "original_sap_text": "Then for Functional scales: Score = {1 - (RS-1)/range} \u00d7 100",
      "protocol_text": null,
      "in_protocol": "no",
      "classification": "acceptable_difference",
      "description": "Specific scoring formula missing.",
      "reasoning": "Not in protocol."
    },
    {
      "component": "QoL Symptom Score Formula",
      "original_sap_text": "And for Symptom scales/items and Global health status/QoL: Score = {(RS-1)/range} \u00d7 100",
      "protocol_text": null,
      "in_protocol": "no",
      "classification": "acceptable_difference",
      "description": "Specific scoring formula missing.",
      "reasoning": "Not in protocol."
    }
  ],
  "issues": [
    {
      "issue_type": "contradiction_original",
      "severity": "minor",
      "component": "TEAE Definition",
      "original_sap_text": "A Treatment-Emergent Adverse Event (TEAE) is defined as any event not present before exposure to study drug or any event already present that worsen in either severity or frequency after exposure to study drug.",
      "generated_sap_text": "A treatment-emergent abnormality is defined as a post-baseline value that represents a worsening from baseline (either an increase in CTCAE grade or a shift from Normal/Low to High, or Normal/High to Low).",
      "protocol_text": "A treatment-emergent AE is defined as any event not present before exposure to study drug or any event already present that worsens in either severity or frequency after exposure to study drug.",
      "why_they_conflict": "Generated SAP defines TEAE only in the context of laboratory abnormalities, missing the broader clinical definition provided in the Original SAP and Protocol.",
      "description": "The definition of TEAE in the Generated SAP is restricted to laboratory abnormalities, whereas the Original SAP and Protocol provide a general definition applicable to all adverse events.",
      "reasoning": "1) Original SAP defines TEAE broadly for all events. 2) Generated SAP defines 'treatment-emergent abnormality' specifically for labs in Section 7.1.3.5 but lacks a general TEAE definition in the safety section. 3) This restricts the scope of TEAEs in the Generated SAP compared to the Original. 4) Both cannot be true as the Generated SAP implies a narrower definition."
    }
  ],
  "extra_information_flagged": [],
  "reasoning": "The Generated SAP correctly identifies the primary and secondary objectives and endpoints. However, it lacks significant detail regarding specific calculations and definitions found in the Original SAP. Specifically, it misses the formulas for time-to-event calculations (days to months conversion), specific censoring rules for TTP and PFS (censoring at randomization for no assessment), and OS censoring rules. It also omits the list of Adverse Events of Special Interest (AESIs), which are explicitly listed in the Protocol and Original SAP. Furthermore, specific formulas for QoL scoring and immunogenicity data transformation are missing. While some of these are acceptable omissions if not in the protocol, the missing AESI list and censoring rules are critical omissions as they are protocol-required or standard analysis definitions.",
  "summary": "The Generated SAP provides a high-level overview of objectives and endpoints but lacks the necessary technical detail and specific definitions present in the Original SAP. Critical omissions include the list of Adverse Events of Special Interest and specific censoring rules for time-to-event analyses, which are required by the protocol."
}